AR and PI3K Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer

Lutetium-177 prostate-specific membrane antigen radioligands ((177)Lu-PSMA) are new therapeutic agents for the treatment of metastatic castration-resistant prostate cancer (mCRPC). We evaluated the prognostic value of circulating tumour DNA (ctDNA) profiling in patients with mCRPC starting treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Vanwelkenhuyzen, Jan, Van Bos, Eva, Van Bruwaene, Siska, Lesage, Karl, Maes, Alex, Üstmert, Sezgin, Lavent, Filip, Beels, Laurence, Grönberg, Henrik, Ost, Piet, Lindberg, Johan, De Laere, Bram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244905/
https://www.ncbi.nlm.nih.gov/pubmed/37292496
http://dx.doi.org/10.1016/j.euros.2023.05.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244905/
https://www.ncbi.nlm.nih.gov/pubmed/37292496
http://dx.doi.org/10.1016/j.euros.2023.05.008

Ejemplares similares